Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed HCC~* Participants were either intermediate HCC of BCLC Stage B, who were not eligible for surgical and/or local-regional therapies or who had progressive disease (PD) after surgical and/or local-regional therapies (note: the local-regional therapy must not contain sorafenib), or advanced HCC of BCLC Stage C~* Participants who had disease progression on or were intolerant to the prior standard treatment for advanced HCC (phase Ib Korean subjects only)~* A tumor biopsy was required for determining MET status~* MET+ status (Phase 2 only), as determined by the central laboratory (Phase 1b retrospectively, Phase 2 for participant selection) were defined in the protocol~* Child-Pugh class A with no encephalopathy according to the screening assessment~* Asian male or female, 18 years of age or older~* Measurable disease in accordance with RECIST v1.1 (Phase 2 only)~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2~* Eligible for treatment with sorafenib, was assessed by investigators according to the Package Insert and clinical judgment (Phase 2 only)~* Signed and dated informed consent indicating that the participants had been informed of all the pertinent aspects of the trial prior to enrollment~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures~* Life expectancy was judged by the investigator of at least 3 months~Exclusion Criteria:~* Prior systemic anticancer treatment for advanced HCC, included targeted therapy (for example, sorafenib), chemotherapy, or any other investigational agent (Phase 2 only)~* Prior treatment with any agent targeting the hepatocyte growth factor (HGF)/c-Met pathway~* Prior local-regional therapy within 4 weeks prior to Day 1 of trial treatment~* Prior history of liver transplant~* Laboratory index at baseline were defined in the protocol~* Past or current history of neoplasm other than HCC, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 5 years~* Known central nervous system (CNS) or brain metastasis that is either symptomatic or untreated~* Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested products~* Clinically significant gastrointestinal bleeding within 4 weeks before trial entry~* Peripheral neuropathy Grade greater than or equal to 2 (Common Terminology Criteria for Adverse Events \[CTCAE\] v4.0)~* Impaired cardiac function was defined in the protocol~* Hypertension uncontrolled by standard therapies~* Participants with a family history of long QT syndrome or who take any agent that is known to prolong QT/QTc interval~* Known human immunodeficiency virus (HIV) infection~* Particpants who had acute pancreatitis and/or chronic pancreatitis, with elevated lipase and/or amylase, clinical symptoms, and/or imaging studies that are indicative of the diagnosis (Mainland Chinese participants only)~* Known or suspected drug hypersensitivity to any ingredients of sorafenib (Phase 2 only) and MSC2156119J~* Female participants who were pregnant or lactating, or males and females of reproductive potential not willing or not able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug~* Concurrent treatment with a non-permitted drug~* Substance abuse, other acute or chronic medical or psychiatric condition, or laboratory abnormalities that may increase the risk associated with trial participation in the opinion of the investigator~* Participation in another clinical trial within the past 28 days~* Previous anticancer treatment-related toxicities not recovered to baseline or Grade 0-1 (except alopecia and peripheral neuropathy)~* Participants with any concurrent medical condition or disease that will potentially compromise the conduct of the study at the discretion of the investigators

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1b: Tepotinib 300 mg (Type: EXPERIMENTAL): Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
- Phase 1b: Tepotinib 500 mg (Type: EXPERIMENTAL): Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
- Phase 1b: Tepotinib 1000 mg (Type: EXPERIMENTAL): Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
- Phase 2: Tepotinib (Type: EXPERIMENTAL): Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
- Phase 2 Sorafenib (Type: EXPERIMENTAL): Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).